Cargando…
Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma
Despite great advancements in the treatment of non-Hodgkin lymphoma (NHL), sensitivity of different subtypes to therapy varies. Targeting the aberrant activation NF-κB signaling pathways in lymphoid malignancies is a promising strategy. Here, we report that 11(13)-dehydroivaxillin (DHI), a natural c...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636986/ https://www.ncbi.nlm.nih.gov/pubmed/28906487 http://dx.doi.org/10.1038/cddis.2017.442 |
_version_ | 1783270553499467776 |
---|---|
author | Xiao, Xinhua Li, Huiliang Jin, Huizi Jin, Jin Yu, Miao Ma, Chunmin Tong, Yin Zhou, Li Lei, Hu Xu, Hanzhang Zhang, Weidong Liu, Wei Wu, Yingli |
author_facet | Xiao, Xinhua Li, Huiliang Jin, Huizi Jin, Jin Yu, Miao Ma, Chunmin Tong, Yin Zhou, Li Lei, Hu Xu, Hanzhang Zhang, Weidong Liu, Wei Wu, Yingli |
author_sort | Xiao, Xinhua |
collection | PubMed |
description | Despite great advancements in the treatment of non-Hodgkin lymphoma (NHL), sensitivity of different subtypes to therapy varies. Targeting the aberrant activation NF-κB signaling pathways in lymphoid malignancies is a promising strategy. Here, we report that 11(13)-dehydroivaxillin (DHI), a natural compound isolated from the Carpesium genus, induces growth inhibition and apoptosis of NHL cells. Multiple signaling cascades are influenced by DHI in NHL cells. PI3K/AKT and ERK are activated or inhibited in a cell type dependent manner, whereas NF-κB signaling pathway was inhibited in all the NHL cells tested. Applying the cellular thermal shift assay, we further demonstrated that DHI directly interacts with IKKα/IKKβ in NHL cells. Interestingly, DHI treatment also reduced the IKKα/IKKβ protein level in NHL cells. Consistent with this finding, knockdown of IKKα/IKKβ inhibits cell proliferation and enhances DHI-induced proliferation inhibition. Overexpression of p65, p52 or RelB partially reverses DHI-induced cell growth inhibition. Furthermore, DHI treatment significantly inhibits the growth of NHL cell xenografts. In conclusion, we demonstrate that DHI exerts anti-NHL effect in vitro and in vivo, through a cumulative effect on NF-κB and other pathways. DHI may serve as a promising lead compound for the therapy of NHL. |
format | Online Article Text |
id | pubmed-5636986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-56369862017-10-12 Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma Xiao, Xinhua Li, Huiliang Jin, Huizi Jin, Jin Yu, Miao Ma, Chunmin Tong, Yin Zhou, Li Lei, Hu Xu, Hanzhang Zhang, Weidong Liu, Wei Wu, Yingli Cell Death Dis Original Article Despite great advancements in the treatment of non-Hodgkin lymphoma (NHL), sensitivity of different subtypes to therapy varies. Targeting the aberrant activation NF-κB signaling pathways in lymphoid malignancies is a promising strategy. Here, we report that 11(13)-dehydroivaxillin (DHI), a natural compound isolated from the Carpesium genus, induces growth inhibition and apoptosis of NHL cells. Multiple signaling cascades are influenced by DHI in NHL cells. PI3K/AKT and ERK are activated or inhibited in a cell type dependent manner, whereas NF-κB signaling pathway was inhibited in all the NHL cells tested. Applying the cellular thermal shift assay, we further demonstrated that DHI directly interacts with IKKα/IKKβ in NHL cells. Interestingly, DHI treatment also reduced the IKKα/IKKβ protein level in NHL cells. Consistent with this finding, knockdown of IKKα/IKKβ inhibits cell proliferation and enhances DHI-induced proliferation inhibition. Overexpression of p65, p52 or RelB partially reverses DHI-induced cell growth inhibition. Furthermore, DHI treatment significantly inhibits the growth of NHL cell xenografts. In conclusion, we demonstrate that DHI exerts anti-NHL effect in vitro and in vivo, through a cumulative effect on NF-κB and other pathways. DHI may serve as a promising lead compound for the therapy of NHL. Nature Publishing Group 2017-09 2017-09-14 /pmc/articles/PMC5636986/ /pubmed/28906487 http://dx.doi.org/10.1038/cddis.2017.442 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Xiao, Xinhua Li, Huiliang Jin, Huizi Jin, Jin Yu, Miao Ma, Chunmin Tong, Yin Zhou, Li Lei, Hu Xu, Hanzhang Zhang, Weidong Liu, Wei Wu, Yingli Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma |
title | Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma |
title_full | Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma |
title_fullStr | Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma |
title_full_unstemmed | Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma |
title_short | Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma |
title_sort | identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-hodgkin's lymphoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636986/ https://www.ncbi.nlm.nih.gov/pubmed/28906487 http://dx.doi.org/10.1038/cddis.2017.442 |
work_keys_str_mv | AT xiaoxinhua identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT lihuiliang identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT jinhuizi identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT jinjin identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT yumiao identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT machunmin identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT tongyin identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT zhouli identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT leihu identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT xuhanzhang identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT zhangweidong identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT liuwei identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma AT wuyingli identificationof1113dehydroivaxillinasapotenttherapeuticagentagainstnonhodgkinslymphoma |